Although there are available treatments for cutaneous leishmaniasis (CL), the drugs used
are far from ideal, toxic, and costly, in addition to the challenge faced by the development of …

A growing number of studies have demonstrated the in vitro potential of an impressive
number of antileishmanial candidates in the past years. However, the lack of uniformity …

Infection with Fasciola hepatica (liver fluke) causes fasciolosis (or fascioliasis) and poses a
considerable economic as well as welfare burden to both the agricultural and animal health …

A promising strategy for developing novel therapies against tropical diseases, including
malaria, leishmaniasis, and trypanosomiasis, is to detect biological targets such as …

Leishmaniasis is a tropical disease caused by parasites of the genus Leishmania spp; it
presents different clinical manifestations, of which cutaneous leishmaniasis is the most …

In the last decade, the World Health Organization has driven the development of drugs for
topical use in patients with cutaneous leishmaniasis (CL), the most prevalent clinical form of …

Within this work, we describe the design and synthesis of a range of novel thiochromanones
based on natural products reported to possess anti-leishmanial action, and their synthetic …

Malachra alceifolia Jacq.(family Malvaceae), known as “malva,” is a medicinal plant used as
a traditional therapy in many regions of America, Africa and Asia. Traditionally, this plant is …

Canine cutaneous leishmaniasis (CCL) is an emerging zoonotic infection endemic in
several countries of the world. Due to variable response to therapy and frequency of …

Context: Cutaneous leishmaniasis is a disease of public health importance; treatment is
based on the use of pentavalent antimonials with high toxicity and low efficacy; therefore, its …